Better Therapeutics (BTTX) Stock Price, News & Analysis

Company Overview

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.27
• Volume: 24,101 shs
• Average Volume: 2.29 million shs
• Market Capitalization: $4,986.20
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTTX Stock Analysis - Frequently Asked Questions

How have BTTX shares performed this year?

Better Therapeutics' stock was trading at $0.1950 at the beginning of the year. Since then, BTTX stock has decreased by 99.9% and is now trading at $0.0001.
View the best growth stocks for 2024 here.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Better Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Better Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Cricut (CRCT), Zomedica (ZOM), Wells Fargo & Company (WFC) and Abbott Laboratories (ABT).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BTTX
• CUSIP: N/A
• CIK: 1832415
• Web: mcacquisition.com
• Phone: 415-887-2311
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 49,862,000
• Free Float: 24,233,000
• Market Cap: $4,986.20
• Optionable: Optionable
• Beta: 1.90